Press Releases :: Lexaria Bioscience Corp. (LEXX)

Apr 14, 2022 8:45am EDT

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

Apr 12, 2022 9:10am EDT

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

Apr 11, 2022 9:00am EDT

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

Mar 15, 2022 2:05pm EDT

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

Mar 08, 2022 9:15am EST

Lexaria Granted Important New Oral Nicotine Patent

Feb 02, 2022 9:25am EST

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

Jan 27, 2022 9:35am EST

Lexaria Provides Annual Letter From the CEO

Jan 18, 2022 9:25am EST

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

Dec 29, 2021 11:15am EST

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

Dec 16, 2021 2:45pm EST

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

rss_feed News RSS